<DOC>
	<DOCNO>NCT00005956</DOCNO>
	<brief_summary>RATIONALE : A person 's white blood cell mixed tumor protein may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness biological therapy treat patient advanced cancer show sign disease follow treatment .</brief_summary>
	<brief_title>Biological Therapy Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate immune response patient HER2/neu express advanced malignancy show evidence disease standard treatment inject HER2/neu intracellular domain protein pulse autologous dendritic cell . - Assess time recurrence patient . OUTLINE : Autologous dendritic cell ( DC ) pulse HER2/neu intracellular domain protein ( ICD ) . The pulsed DC administer subcutaneously ( SQ ) intradermally , follow autologous DC mixed tetanus toxoid ( TT ) autologous DC mixed keyhole limpet hemocyanin ( KLH ) SQ intradermally day 1 . HLA-A2 positive patient also receive autologous DC mixed CMV pp65 peptide SQ intradermally day 1 . Treatment continue every 3 week total 4 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year disease progression . PROJECTED ACCRUAL : A total 6 patient accrue study 6 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced malignancy express HER2/neu Stage IIA breast cancer 6 positive lymph node Stage IIB , IIIA , IIIB breast cancer Stage III ovarian cancer Lymph node positive gastric cancer Metastatic tumor No measurable evaluable disease standard treatment No previously irradiate newly diagnose CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : Karnofsky 80100 % Life expectancy : Greater 6 month Hematopoietic : WBC least 3,000/mm^3 Hemoglobin least 9 mg/dL Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL No hepatic disease , include viral hepatitis Renal : Creatinine le 2.5 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease Pulmonary : No asthma chronic obstructive pulmonary disease Immunologic : Must positive intradermal delay hypersensitivity test least 1 follow : Candida Mumps Tetanus Trichophyton Histoplasmin No prior autoimmune disease include , limited , follow : Inflammatory bowel disease Systemic lupus erythematosus Ankylosing spondylitis Scleroderma Multiple sclerosis Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative Hepatitis B surface antigen hepatitis C antibody negative No concurrent serious chronic acute illness infection ( include urinary tract infection ) No know shellfish iodine allergy No prior concurrent malignancy except nonmelanoma skin cancer , cervical cancer , control superficial bladder cancer No medical psychological condition may preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : Concurrent hormonal therapy allow ( tamoxifen , raloxifene , toremifene , aromatase inhibitor ) At least 4 week since prior steroid immunosuppressive therapy ( e.g , azathioprine cyclosporine ) Radiotherapy : Prior radiotherapy allow except cranium At least 4 week since prior radiotherapy recover At least 12 week since prior strontium chloride Sr 89 No concurrent radiotherapy Surgery : At least 4 week since prior surgery recover Other : Concurrent bisphosphonates allow No prior hepatitis B immunization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>